Cerity Partners
KROS icon

Cerity Partners’s Keros Therapeutics KROS Stock Holding History

Cerity Partners’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$196K Buy
+18,301
New +$204K ﹤0.01% 3058

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Cerity Partners's KROS Position: Q2 2026 in Review

Cerity Partners opened a new position in Keros Therapeutics (KROS) in Q2 2026: 18,301 shares worth $196K. The stake represents ﹤0.01% of the portfolio and ranks #3058 among its holdings.

132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Cerity Partners held 18,301 shares of Keros Therapeutics worth $196K as of Q2 2026.
  • Keros Therapeutics was a new Cerity Partners position in Q2 2026.
  • Keros Therapeutics made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #3058 holding.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.